Type
- Cancellation by sponsor (493)
- ARTG (489)
- Australian Public Assessment Report (AusPAR) (65)
- Prescription medicine registration (42)
- Section 14, TGO91 consent (21)
- Prescription medicine decision summary (19)
- Designation or determination (9)
- Cancellation or suspension (7)
- Prescription medicine evaluation (1)
Date
- 2025 (7)
- 2024 (87)
- 2023 (73)
- 2022 (61)
- 2021 (126)
- 2020 (107)
- 2019 (98)
- 2018 (97)
- 2017 (74)
- 2016 (12)
- 2015 (22)
- 2014 (23)
- 2013 (9)
- 2012 (9)
- 2011 (14)
- 2010 (29)
- 2009 (13)
- 2008 (6)
- 2007 (11)
- 2006 (8)
- 2005 (4)
- 2004 (8)
- 2003 (9)
- 2002 (12)
- 2001 (8)
- 2000 (22)
- 1999 (9)
- 1998 (12)
- 1997 (18)
- 1996 (8)
- 1995 (3)
- 1994 (33)
- 1993 (19)
- 1992 (8)
- 1991 (87)
Sponsor content
1146 result(s) found, displaying 231 to 240
-
Prescription medicine registrationActive ingredients: daptomycin.
-
Australian Public Assessment Report (AusPAR)Australian Public Assessment Report for Tozinameran
-
Cancellation by sponsorRequested by Pfizer Australia Pty Ltd
-
Cancellation by sponsorRequested by Pfizer Australia Pty Ltd
-
Cancellation by sponsorRequested by Pfizer Australia Pty Ltd
-
Cancellation by sponsorRequested by Pfizer Australia Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TUKYSA tucatinib 50 mg film-coated tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TUKYSA tucatinib 150 mg film-coated tablet blister pack.
-
Australian Public Assessment Report (AusPAR)Australian Public Assessment Report for nirmatrelvir/ritonavir
-
Prescription medicine decision summaryTGA decision: Paxlovid (nirmatrelvir/ritonavir) is approved for the treatment of adults with COVID-19.